Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)
China · Delayed Price · Currency is CNY 2.920
-0.020 (-0.68%)
Jun 2, 2026, 3:04 PM CST
SHE:002589 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 7,167 | 7,217 | 7,904 | 7,976 | 12,264 | 20,913 |
Other Revenue | 79.32 | 79.32 | 62.07 | 57.97 | 47.5 | 146.6 |
| 7,247 | 7,296 | 7,967 | 8,034 | 12,311 | 21,060 | |
Revenue Growth (YoY) | -5.94% | -8.42% | -0.84% | -34.74% | -41.54% | -22.67% |
Cost of Revenue | 6,502 | 6,526 | 7,096 | 7,212 | 10,683 | 17,315 |
Gross Profit | 744.89 | 769.9 | 870.93 | 822.06 | 1,628 | 3,745 |
Selling, General & Admin | 607.13 | 653.45 | 752.66 | 835.99 | 1,503 | 2,668 |
Research & Development | 18.69 | 20.91 | 18.27 | 14.62 | 22.68 | 11.56 |
Other Operating Expenses | 35.96 | 36.59 | 36.91 | 45.72 | 52.13 | 93.7 |
Operating Expenses | 675.81 | 697.64 | 850.96 | 906.33 | 1,737 | 2,932 |
Operating Income | 69.08 | 72.26 | 19.97 | -84.27 | -108.72 | 813.41 |
Interest Expense | -158.64 | -178.86 | -194.08 | -303.7 | -407.71 | -554.42 |
Interest & Investment Income | 137.14 | 163.02 | 184.11 | 599.53 | 83.97 | 251.17 |
Currency Exchange Gain (Loss) | - | - | -0.02 | 0 | -0 | 0.01 |
Other Non Operating Income (Expenses) | -52.16 | -55.54 | -47.4 | -77.37 | -169.88 | -121.5 |
EBT Excluding Unusual Items | -4.58 | 0.89 | -37.42 | 134.19 | -602.33 | 388.68 |
Impairment of Goodwill | - | - | - | -0.02 | -22.94 | -39.67 |
Gain (Loss) on Sale of Investments | 5.79 | 4.9 | 30.65 | -261.66 | -1,087 | 82.15 |
Gain (Loss) on Sale of Assets | 2 | 1.82 | 18.94 | -7.92 | -1 | 3.06 |
Asset Writedown | -0.71 | -0.71 | -0.61 | -4.89 | -24.89 | -0.24 |
Other Unusual Items | -4.15 | -4.21 | 19.09 | 4.89 | -4.98 | 31.04 |
Pretax Income | -1.65 | 2.69 | 30.64 | -135.42 | -1,744 | 465.02 |
Income Tax Expense | -44.47 | -41.21 | 0.58 | -167.39 | -4.88 | 83.01 |
Earnings From Continuing Operations | 42.83 | 43.9 | 30.06 | 31.97 | -1,739 | 382.01 |
Minority Interest in Earnings | -28.47 | -27.83 | -17.77 | -11.65 | -92.17 | -250.83 |
Net Income | 14.35 | 16.07 | 12.29 | 20.32 | -1,831 | 131.18 |
Net Income to Common | 14.35 | 16.07 | 12.29 | 20.32 | -1,831 | 131.18 |
Net Income Growth | 55.80% | 30.73% | -39.49% | - | - | -49.80% |
Shares Outstanding (Basic) | 1,605 | 1,607 | 1,229 | 1,505 | 1,477 | 1,458 |
Shares Outstanding (Diluted) | 1,605 | 1,607 | 1,229 | 1,505 | 1,477 | 1,458 |
Shares Change (YoY) | 30.32% | 30.73% | -18.31% | 1.93% | 1.30% | 0.40% |
EPS (Basic) | 0.01 | 0.01 | 0.01 | 0.01 | -1.24 | 0.09 |
EPS (Diluted) | 0.01 | 0.01 | 0.01 | 0.01 | -1.24 | 0.09 |
EPS Growth | 19.55% | - | -25.93% | - | - | -50.00% |
Free Cash Flow | -40.57 | -13.06 | 49.22 | -215.92 | 352.11 | -18.13 |
Free Cash Flow Per Share | -0.03 | -0.01 | 0.04 | -0.14 | 0.24 | -0.01 |
Dividend Per Share | 0.002 | 0.002 | 0.011 | 0.013 | - | 0.009 |
Dividend Growth | -81.82% | -81.82% | -15.38% | - | - | -50.00% |
Gross Margin | 10.28% | 10.55% | 10.93% | 10.23% | 13.23% | 17.78% |
Operating Margin | 0.95% | 0.99% | 0.25% | -1.05% | -0.88% | 3.86% |
Profit Margin | 0.20% | 0.22% | 0.15% | 0.25% | -14.87% | 0.62% |
Free Cash Flow Margin | -0.56% | -0.18% | 0.62% | -2.69% | 2.86% | -0.09% |
EBITDA | 206.61 | 221.5 | 216.06 | 130.9 | 165.95 | 1,113 |
EBITDA Margin | 2.85% | 3.04% | 2.71% | 1.63% | 1.35% | 5.29% |
D&A For EBITDA | 137.53 | 149.24 | 196.09 | 215.17 | 274.67 | 299.78 |
EBIT | 69.08 | 72.26 | 19.97 | -84.27 | -108.72 | 813.41 |
EBIT Margin | 0.95% | 0.99% | 0.25% | -1.05% | -0.88% | 3.86% |
Effective Tax Rate | - | - | 1.89% | - | - | 17.85% |
Revenue as Reported | 7,247 | 7,296 | 7,967 | 8,034 | 12,311 | 21,060 |